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Abstract
T-cell exclusion from the tumor microenvironment (TME) is a
major barrier to overcoming immune escape. Here, we identify a
myeloid-intrinsic mechanism governed by the NF-kB effector
moleculeGADD45b that restricts tumor-associated inﬂammation
and T-cell trafﬁcking into tumors. In various models of solid
cancers refractory to immunotherapies, including hepatocellular
carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in
myeloid cells restored activation of proinﬂammatory tumor-
associated macrophages (TAM) and intratumoral immune inﬁl-
tration, thereby diminishing oncogenesis. Our results provide a
basis to interpret clinical evidence that elevated expression of
GADD45B confers poor clinical outcomes inmost human cancers.
Furthermore, they suggest a therapeutic target in GADD45b for
reprogramming TAM to overcome immunosuppression and
T-cell exclusion from the TME.
Signiﬁcance: These ﬁndings deﬁne a myeloid-based immune
checkpoint that restricts T-cell trafﬁcking into tumors, with
potentially important therapeutic implications to generally
improve the efﬁcacy of cancer immunotherapy. Cancer Res; 78(5);
1275–92. 2017 AACR.
Introduction
Virtually all tumors contain an inﬂammatory inﬁltrate of innate
and adaptive immune cells (1). Despite their inherent capacity to
counter neoplastic progression and eliminate nascent tumors,
these cells, especially those of the innate immune system, often
have the effect of promoting oncogenesis (1, 2). Accordingly,
tumor-associated inﬂammation is now considered a hallmark of
cancer (1). The ability of the immune system to inﬂuence onco-
genesis is currently being exploited to treat cancer patients,with the
development ofmany successful anticancer immunotherapies (3).
Indeed, therapies blocking pivotal immunoinhibitory mechan-
isms, comprising immune checkpoint molecules, for example,
cytotoxic T lymphocyte antigen-4 (CTLA-4) or programmed cell
death protein 1 (PD-1), are revolutionizing the clinical manage-
ment of certain malignancies, such as metastatic melanoma (4).
However, major challenges remain, as the majority of patients
rarely exhibit an objective response to these treatments, due to the
absence of a preexisting intratumoral T-cell inﬁltrate or, in patients
with T-cell–inﬁltrated tumors, the dominant inhibitory effects of
additional tumormicroenvironment (TME)–associatedmolecules
(3, 5). Yet, the mechanisms underlying the immunoinhibitory
activities of the TME are presently poorly understood.
Tumor-associated macrophages (TAM) are implicated in var-
ious TME-mediated mechanisms that enable cancers to evade
immune attack (3, 6, 7). TAMs are themain leukocyte population
found in most human tumors, where they play a key role in
restricting local T-cell trafﬁcking and T-cell effector functions
(3, 6, 7). Indeed, a high density of TAMs, especially those exhibit-
ing an anti-inﬂammatory and immunosuppressive phenotype,
correlates with poor clinical outcome in most human cancers
(7, 8). Accordingly, therapeutic approaches limiting myeloid cell
recruitment into tumors have resulted in increased TME-based
CD8þ effector T-cell inﬁltration and diminished tumor burden
in mouse models and early-phase clinical trials (3, 6, 9–13).
However, the general macrophage depletion associated with
these approaches raises important safety concerns. Therefore,
a preferable approach would be to reprogram TAMs toward
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a proinﬂammatory phenotype capable of redirecting T-cell traf-
ﬁcking into tumors and unleashing local antitumor immune
responses (6, 14).
Macrophages can differentiate into a spectrum of phenotypic
states in response to diverse environmental signals. At sites of
infection, "classically" activated or proinﬂammatorymacrophages
(hereafter also occasionally referred to as M1-like macrophages)
arise in response to IFNg and Toll-like receptor (TLR) ligands to
eliminate invading pathogens, promote inﬂammation, and
engage the adaptive immune system. In contrast, "alternatively"
activated or anti-inﬂammatory macrophages (hereafter also occa-
sionally referred to asM2-likemacrophages) are "educated" by IL4
and IL13 at sites of injury to terminate inﬂammation and enable
wound healing (7, 8). Interestingly, anti-inﬂammatory macro-
phages resemble the TAMs found in most human cancers, where
they support tumor progression, metastatic dissemination, and
cancer immune evasion (7, 8). However, little is known about
the mechanisms governing the opposing functions of macro-
phages in response to tissue injury, malignancy, or infection.
Consequently, there are presently no therapeutic agents capable
of effectively reprogramming TAMs to oppose oncogenesis.
Recent studies have identiﬁed NF-kB transcription factors as
key determinants in the balance between proinﬂammatory and
anti-inﬂammatory macrophage activation in response to infec-
tion or tumor-derived signals (15, 16). In fact, in addition to
orchestrating protective immune and inﬂammatory responses,
theNF-kBpathway drives oncogenesis inmultiple cancer types by
suppressing apoptosis of tumor cells and, concurrently, governing
TME-based inﬂammation, thereby serving as a central hub linking
cancer and inﬂammation (16, 17). In ovarian adenocarcinoma
models, macrophage-speciﬁc inhibition of the NF-kB–activating
kinase, IkBa kinase (IKK)b, was shown to reverse the anti-
inﬂammatory TAM phenotype and enhance proinﬂammatory
macrophage activation, thereby causing tumor regression (18).
A similar conversion from an anti-inﬂammatory TAM activa-
tion state supportive of oncogenesis to a proinﬂammatory
activation state that antagonizes tumor growth was reported
in melanoma and ﬁbrosarcoma models in mice bearing TAMs
lacking NF-kB1/p105 (19). Notably, this IKKb/NF-kB function
in suppressing proinﬂammatory activation was shown to
extend beyond the cancer context, reﬂecting the tissue-speciﬁc
role that IKKb/NF-kB plays in myeloid cells, where opposite to
its conventional proinﬂammatory role, NF-kB drives the reso-
lution of inﬂammation to enable wound healing and prevent
tissue damage (20, 21).
Therefore, the IKKb/NF-kB pathway provides an attractive
route to therapeutically reverse TME-mediated immunosuppres-
sion by reprogramming TAMs toward a proinﬂammatory phe-
notype (15, 18). However, therapeutically targeting this pathway
with conventional IKKb/NF-kB inhibitors has not proven possi-
ble, due to the severe on-target toxicities associated with globally
suppressing NF-kB (17). A logical alternative to pharmacologi-
cally inhibiting IKKb/NF-kB would be therefore to target the
nonredundant downstream effectors of the NF-kB anti-inﬂam-
matory function in myelomonocytic cells. However, these effec-
tors and their modes of action remain poorly understood.
Here, we report that the NF-kB–regulated protein, GADD45b
(22, 23), mediates an essential myeloid-intrinsic mechanism
governing proinﬂammatory macrophage activation and the
immunosuppressive activity of the TME that restrict CD8þ T-cell
trafﬁcking into tumors. Using three distinct models of solid
cancers that are largely refractory to immunotherapies, including
hepatocellular carcinoma (HCC) and ovarian adenocarcinoma,
we showed that Gadd45b deletion in myeloid cells restores
proinﬂammatory TAM activation and intratumoral CD8þ
T-lymphocyte inﬁltration, resulting in diminished tumor growth.
Because we previously showed that GADD45b additionally med-
iates the NF-kB antiapoptotic activity in cancer cells (24), our
current ﬁndings identify GADD45b as a pivotal downstream hub
integrating the NF-kB oncogenic functions linking cancer and
inﬂammation. Our ﬁnding that elevated GADD45B expression
correlateswith poor clinical outcomes acrossmost human cancers
consolidates the general clinical signiﬁcance of the GADD45b-
mediated oncogenic mechanism in malignant disease. Together,
these results reveal a pathogenically critical, innate immunity
"checkpoint" governed by GADD45b that is amenable to thera-
peutic intervention to "re-educate" TAMs and ultimately over-
come TME-dependent immunosuppression, with profound
implications for anticancer therapy.
Materials and Methods
Human cancer datasets
The human datasets of lung cancer (LUNG), stomach adeno-
carcinoma (STAD), nonalcoholic liver hepatocellular carcinoma
(LIHC), esophageal carcinoma (ESCA), cervical carcinoma
(CESC), untreated primary glioblastoma multiforme (GBM),
cholangiocarcinoma (CHOL), head and neck squamous cell
carcinoma (HNSC), and kidney clear cell carcinoma (KIRC) were
part of The Cancer Genome Atlas (25) program and downloaded
from the UCSC Cancer Genomic Browser (26). Gene expression
proﬁling was performed on fresh or frozen tissue biopsies using
the Illumina HiSeq 2000 RNA Sequencing platform. The esti-
mates of GADD45B expression levels were derived from the
normalized values in the UCSC Cancer Genomic Browser. The
datasets of colon adenocarcinoma (COAD; GSE39582), bladder
carcinoma (BLCA; GSE13507) and ovarian cancer (OV;
GSE9891) were deposited in the National Center for Biotechnol-
ogy Information (NCBI) Gene Expression Omnibus (GEO) data-
base (www.ncbi.nlm.nih.gov/geo). The COAD dataset was from
the French national Cartes d'Identite des Tumeurs (CIT) program
and generated using the Affymetrix Human Genome U133 Plus
2.0 Array platform (27). The BLCA dataset was from the Chung-
buk National University Hospital (Cheongju, South Korea) and
generated using the Illumina human-6 v2.0 expression beadchip
platform (28). The OV dataset was from the Australian Ovarian
Cancer Study, Royal Brisbane Hospital (Queensland, Australia),
Westmead Hospital (Sydney, Australia), and Netherlands Cancer
Institute (Amsterdam, Netherlands) and generated using the
Affymetrix Human Genome U133 Plus 2.0 Array platform
(29). The relative GADD45B mRNA expression levels in these
datasets were derived from the normalized values present in the
GEO database. The breast carcinoma dataset (BRCA) was from
the tumor banks in the United Kingdom and Canada, and
gene proﬁling data were generated using the Illumina
HumanHT-12 V3 platform and deposited onOncomine Research
Premium Edition (30).
The gene proﬁling data from each dataset were downloaded
together with the accompanying clinical information. Where
possible, the series were obtained frompatients at an early disease
stage and datasets with a sufﬁcient number of patients with
recurrence-free survival (RFS) information. In the other cases,
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where this was not possible, the series consisted of overall survival
(OS) data and/or the entire patient dataset. Patientswere stratiﬁed
into two groups on the basis of the GADD45B mRNA expression
levels. In each case, quintiles, quartiles, tertiles, and 95th
percentiles were used as thresholds, and the best ﬁts are reported
in Fig. 1A–M.
Cell culture and macrophage isolation and treatment
The C57BL/6 mouse ﬁbrosarcoma cell line, MCA-203, was
kindly provided by I. Marigo and V. Bronte (Department of
Oncology and Surgical Sciences, University of Padua, Padua,
Italy) and cultured in high-glucose DMEM (with L-glutamine,
without sodium pyruvate; Gibco) supplemented with 10%
heat-inactivated FBS (Sigma-Aldrich), antibiotics (150 U/mL
penicillin, 200 U/mL streptomycin), 10 mmol/L HEPES
(Gibco), 2 mmol/L b-mercaptoethanol, and 2 mmol/L L-gluta-
mine (Gibco). The C57BL/6 mouse ovarian carcinoma cell line,
ID8-Luc, stably expressing ﬁreﬂy luciferase (Luc), was described
previously (18) and cultured in high-glucose DMEM (with L-
glutamine, without sodium pyruvate; Gibco) supplemented
with 4% heat-inactivated FBS (Sigma-Aldrich), antibiotics
(150 U/mL penicillin, 200 U/mL streptomycin), ITSþ1 Liquid
Media Supplement (5 mg/mL insulin, 5 mg/mL transferrin, 5 ng/
mL sodium selenite; Sigma-Aldrich), and 2 mmol/L L-gluta-
mine (Gibco). Cells were cultured in a humidiﬁed incubator in
5% CO2 at 37C. All cell lines were routinely tested using a
Mycoplasma Detection Kit (ATCC). Before injection in vivo, cell
lines were also routinely screened for other infectious agents
using the Mouse Essential CLEAR Panel (Charles River Labo-
ratories). The cell line authentication for the MCA-203 and ID8-
Luc murine cell lines has not been possible because these cell
lines are not commercially available. Cells were used for the
experiments between 5 and 7 days upon thawing.
Bone marrow–derived macrophages (BMDM) were prepared
from 6- to 10-week old Gadd45b/ and Gadd45bþ/þ C57BL/6J
mice as described previously (21). BMDMs were treated with LPS
(E. coli serotype O55:B5, 100 ng/mL; Sigma-Aldrich) and mouse
recombinant IFNg (20 ng/mL; Sigma-Aldrich) or with mouse
recombinant IL4 (20 ng/mL; Peprotech) andmouse recombinant
IL13 (20 ng/mL; Peprotech). The p38 inhibitors used were Vx745
(20 mmol/L; Selleckchem), Skepinone-L (10 mmol/L; Selleck-
chem), and SB203580 (20 mmol/L; Cell Signaling Technology).
For TAM isolation, intraperitoneal cells were harvested from
ID8-Luc tumor-bearing mice by peritoneal lavage with 1 PBS
and passed through a 70-mm cell strainer (BD Biosciences),
following red blood cell removal with RBC lysis buffer (Sigma-
Aldrich). TAMs were separated using MACS MicroBead Technol-
ogy (Miltenyi Biotec) by negative selection with anti–Ly-6G
MicroBeadKit,mouse, followed bypositive selectionwithCD11b
MicroBeads, human and mouse (Miltenyi Biotec), according to
the manufacturer's instructions.
Further information on the procedures for BMDMisolation can
be found in the Supplementary Information.
BMDM/tumor cell coculture
Gadd45b/ and Gadd45bþ/þ BMDMs were prepared as above
and cocultured with ID8-Luc or MCA-203 tumor cells, without
direct cell-to-cell contact, according to established protocols
(18, 31). Further information on the procedures for BMDM/
tumor cell coculture can be found in the Supplementary
Information.
Mice
C57BL/6Jx129/SvJGadd45b/micewere described previously
(32).Gadd45bþ/þ littermates were cohoused andused as controls.
C57BL/6J Gadd45b/ and Gadd45bþ/þ mice were obtained by
backcrossing the corresponding C57BL/6Jx129/SvJ lines onto
C57BL/6J to at least the N14 backcross generation. C57BL/6J
CD45.1/Ly5.1þ mice (B6.SJL-Ptprca Pepcb/BoyJ) and C57BL/6J
LysM-cre transgenic mice were purchased from The Jackson
Laboratory. C57BL/6J Gadd45b/ and Gadd45bþ/þmice, expres-
sing eitherCD45.2/Ly5.2þorCD45.1/Ly5.1þ, were cohoused and
bred as separate colonies.
Conditional Gadd45b knockout mice, carrying loxP-ﬂanked
Gadd45b alleles (Gadd45bF), were generated at Taconic Bios-
ciences using conventional gene targeting technology in embry-
onic stem (ES) cells. HomozygousGadd45bF/Fmicewere obtained
by the interbreeding of Gadd45bF/þ mice. Gadd45bDM/DM mice,
speciﬁcally lacking Gadd45b in the myeloid lineage, were gener-
ated by crossing Gadd45bF/F mice with C57BL/6J LysM-cre mice
(The JacksonLaboratory), expressing aCre recombinase transgene
under the control of the myeloid-speciﬁc LysM promoter (33).
Cohoused Gadd45bF/F littermates were used as controls for
the experiments.
Mice were housed in ventilated cages in a pathogen-free mouse
facility of the Central Biomedical Services at Imperial College
London (London, United KIngdom) and used in accordance with
established institutional guidelines, under the authority of UK
Home Ofﬁce project license, P75F16A53 [see Guidelines on the
Operation of Animals (Scientiﬁc Procedures) Act of 1986]. Sep-
arate mouse colonies were maintained in ﬁltered top cages on
autoclaved food, water, and bedding in the Conventional Mouse
Facility at the University of L'Aquila (L'Aquila, Italy), and exper-
imental procedures were performed in accordance with national
and international laws and regulations (see European Economic
Community Council Directive 86/609,OJ L 358, 1, December 12,
1987; Italian Legislative Decree 116/92, Gazzetta Ufﬁciale della
Republica Italiana no.40, February 18, 1992; National Institutes
of Health Publication no.85-23, 1985), under the approval of the
University of L'Aquila Internal Committee and the Italian Min-
istry of Health.
Further information on the procedures used for the generation
of Gadd45bF/F mice can be found in the Supplementary
Information.
Bone marrow chimeras
Congenic CD45.1/Ly5.1þGadd45b/ and Gadd45bþ/þ mice
were generated by crossing the corresponding C57BL/6J lines
(CD45.2/Ly5.2þ) with C57BL/6J B6.SJL-Ptprca Pepcb/BoyJ mice
(The Jackson Laboratory), carrying homozygous Ptprca (CD45.1/
Ly5.1) alleles and used as donors in bone marrow adoptive
transfer experiments to distinguish between hematopoietic-
derived cells of recipient (CD45.2/Ly5.2þ) and donor
(CD45.1/Ly5.1þ) origin. For these experiments, bone marrow
cells were harvested from femurs and tibiae of 6- to 10-week old
CD45.1/Ly5.1þGadd45b/ or Gadd45bþ/þ males under aseptic
conditions. Red blood cells were lysed using RBC lysis buffer
(Sigma-Aldrich), washed in serum-free medium, counted, and re-
suspended in 1 PBS. 4 (Protocol A) or 16 (Protocol B)-week-old
C57BL/6J Gadd45b/ and Gadd45bþ/þ male recipients, carrying
Ptprcb (CD45.2/Ly5.2) alleles, were lethally irradiatedwith a single
dose of 9.5 Gy and, 24 hours later, intravenously injected via the
tail veinwith5106bonemarrowdonor cells, to generate all four
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possible chimerism combinations. Bone marrow reconstitution
with CD45.1/Ly5.1þ donor cells was veriﬁed after adoptive trans-
fer by FACS analysis of blood leukocytes.
DEN treatment and HCC induction
For the initiation-only model of HCC, 15- to 17-day old
Gadd45b/ and Gadd45bþ/þ males on a C57Bl/6Jx129/SvJ or
Figure 1.
The widespread correlation between elevated GADD45B expression and poor clinical outcome across human cancer types. A–M, RFS and OS in patients
with the indicated malignant pathologies, representing 13 of the top 15 solid cancers for mortality worldwide and deposited in the following publicly
available datasets: The Cancer Genome Atlas program (A, B, C, F, G, H, K, L, and M); the French National Cartes d'Identite des Tumeurs program (D); the Tumour
Banks in the United Kingdom and Canada (E); the Chungbuk National University Hospital (I); and the Australian Ovarian Cancer Study, Royal Brisbane
Hospital, Westmead Hospital and Netherlands Cancer Institute (J). Patients in each series were stratiﬁed at diagnosis in two groups on the basis of the GADD45B
mRNA expression in the tumor tissues, as shown. P values are indicated.
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C57Bl/6J background, as indicated, were injected intraperitone-
ally with a single dose of diethylnitrosamine (DEN; 5 and
20 mg/kg, respectively; Sigma-Aldrich). At the indicated end-
points, mice were sacriﬁced and their livers removed, photo-
graphed, and separated into individual lobes. Externally visible
tumors (0.5 mm) were measured using a caliper and counted.
Tumor areas were calculated using the formula: p(diameter 1 þ
diameter 2)2/4 (34). For histologic evaluations, liver tissue
was ﬁxed in 10% neutral-buffered formalin solution and
parafﬁn embedded. The remaining liver tissuewasmicrodissected
into tumor and nontumor tissue and stored at 80C for molec-
ular evaluation.
For HCC induction in the tumor initiation–promotion model,
mice were treated according to two distinct experimental setups,
designated as Protocol A and Protocol B. As part of Protocol A,
4-week-old C57BL/6J males (CD45.2/Ly5.2þ) were adoptively
transferred with bone marrow from CD45.1/Ly5.1þ males, and,
4 weeks later, intravenously treated twice with of 200 mL of
clodronate liposomes to deplete endogenous Kupffer cells. Clo-
dronate liposomes, containing approximately 5 mg/mL of
clodronate, were prepared as described previously and were
provided by N. Van Rooijen (ClodronateLiposomes.org; ref. 35).
Ten weeks after clodronate liposome administration, bone mar-
row chimeras were intraperitoneally injected with a single dose of
DEN (100 mg/kg; Sigma-Aldrich) and, 4 weeks later, placed on
treatment with 0.07% of the tumor promoter, phenobarbital
(Sigma-Aldrich), in the drinking water until the experimental
endpoint, according to an established tumor initiation–promo-
tion protocol (33). As part of Protocol B, 4-week-old C57BL/6J
males (CD45.2/Ly5.2þ) were intraperitoneally injected with
75 mg/kg of DEN (Sigma-Aldrich) and, 4 weeks later, placed on
treatment with 0.07% phenobarbital (Sigma-Aldrich) in the
drinking water, as above, to induce HCC initiation and early
promotion. After 8 weeks, mice were adoptively transferred with
bone marrow from congenic CD45.1/Ly5.1þmales and, 4 weeks
later, treated with 200 mL of clodronate liposomes, as above, to
deplete Kupffer cells. At the indicated endpoints, mice were
sacriﬁced, and their livers removed, photographed, and separated
into individual lobes. Externally visible tumors (0.5 mm) were
counted. For histologic evaluations, liver tissue was ﬁxed and
parafﬁn-embedded or embedded in Tissue-Tek OCT compound
(Sakura Finetek) for frozen block preparation. Bone marrow–cell
reconstitution and liver repopulation with donor-derived
CD45.1/Ly5.1þ Kupffer cells were conﬁrmed in each group of
bone marrow chimaeras by FACS analysis of spleen and bone
marrow cells and immunoﬂuorescence staining of frozen liver
sections, respectively.
To validate the procedure for Kupffer cell depletion, a separate
group of C57BL/6J mice was intravenously injected with a single
dose of 200 mL of clodronate or PBS liposomes. At the indicated
time points,micewere sacriﬁced, and their livers and spleenswere
removed, ﬁxed and parafﬁn-embedded for immunohistologic
evaluation of macrophage depletion.
Tumor allografts
For ﬁbrosarcoma allografts, 6- to 8-week-old C57BL/6J
Gadd45b/ and Gadd45bþ/þ males were subcutaneously
injected in the right ﬂank with 1.0  105 MCA-203 cells in
100 mL of sterile 1 PBS, using a 1-mL Leur-Lok Tip syringe (BD
Biosciences) with a 25-guage needle. MCA-203 cells were
harvested from exponentially growing cultures, washed once
with serum-free medium, and resuspended in 1 PBS imme-
diately before injection. Once tumors became palpable, tumor
growth was monitored every other day using a vernier caliper.
Tumor volumes were calculated using the formula: volume ¼
A  B2/2 (where A is the larger diameter, and B is the smaller
diameter of the tumor; ref. 24). Nineteen days after tumor cell
injection, mice were sacriﬁced, and tumors were removed and
embedded in Tissue-Tek OCT compound (Sakura Finetek) for
frozen block preparation. To investigate the macrophage-spe-
ciﬁc role of GADD45b in sarcomagenesis, 6- to 8-week-old
Gadd45bF/F and Gadd45bD/D males were injected with 1.0  105
exponentially growing MCA-203 cells in 200 mL of sterile 1
PBS containing Matrigel (1:1; Corning). Tumor growth was
monitored using a vernier caliper, and tumor volumes were
calculated as above. At the indicated endpoint, mice were
sacriﬁced, and tumors were photographed.
For the in vivo depletion of CD8þ T cells, 8- to 12-week-old
C57BL/6J Gadd45b/ and Gadd45bþ/þ female mice were
treated intraperitoneally with 250 mg of anti-CD8b antibody
(Lyt 3.2; clone 53-5.8; Bio X Cell) or rat IgG isotype-matched
control antibody (clone HRPN; Bio X Cell) at day 1 and day
0 before the injection of 1.0  105 exponentially growing
MCA-203 cells prepared as described above, and then twice a
week with the same dose of antibody until the experimental
endpoint. Tumor growth was monitored as described above.
The efﬁciency of the antibody-mediated CD8þ T-cell
depletion was determined by FACS analysis of spleen cells
using anti–CD8b-APC (130-106-315), anti–CD4-APC (130-
109-415), and anti–CD3-FITC (130-108-836) antibodies
(Miltenyi Biotec).
For ovarian carcinoma allografts, 11- to 12-week-old C57BL/6J
Gadd45b/ and Gadd45bþ/þ females were intraperitoneally
injected with exponentially growing 1.0  106 ID8-Luc cells in
300mLof sterile saline solution, using a 1-mLLeur-Lok Tip syringe
(BD Biosciences) with a 25-guage needle. Tumor growth was
monitored weekly starting 6 weeks after tumor cell injection by
bioluminescence imaging.
The analyses of the macrophage-speciﬁc role of GADD45b in
ovarian oncogenesis were performed essentially as described
previously (18). Brieﬂy, 8-week-old C57BL/6J Gadd45bþ/þ
females (Harlan Laboratories) were intraperitoneally injected
with 2  106 exponentially growing ID8-Luc cells in 300 mL of
sterile saline solution, and tumorswere allowed to grow, as above.
After 5 weeks, mice were randomized into two groups
and intraperitoneally injected with 10  106 BMDMs from
C57BL/6J Gadd45b/ or Gadd45bþ/þ mice in 300 mL of sterile
saline solution. ID8-Luc tumor growth was monitored weekly
by bioluminescence imaging. Further information on the
procedures used for bioimaging can be found in the Supplemen-
tary Information.
Histopathologic analyses, IHC, immunoﬂuorescence, and
TUNEL assays
Detailed information on the procedures used for histopatho-
logic analyses, IHC, immunoﬂuorescence, and TUNEL assays can
be found in the Supplementary Information.
qRT-PCR analysis, Western blots, and FACS analysis
Detailed information on the procedures used for RNA extrac-
tion, qRT-PCR reactions, Western blotting, and FACS analysis can
be found in the Supplementary Information.
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Statistical analysis
Data were analyzed using GraphPad Prism version 7.0
(GraphPad Software) or R (www.R-project.org). Statistical anal-
yses of the results were performed using either two-tailed t tests or
two-tailed Mann–Whitney U test, depending on the distribution
of the data. Assumptions concerning the data (e.g., normal
distribution and similar variation between experimental groups)
were examined for appropriateness before statistical tests
were conducted. P values <0.05 were considered statistically
signiﬁcant. For ovarian carcinoma allografts, outliers were
detected and removed according to the default options of the
software used.
Survival analyses were performed in R, using package survival.
Differences between the survival distributions within each dataset
were assessed for statistical signiﬁcance using Kaplan–Meier
curves and the log-rank test, with P < 0.05 taken as the level
of signiﬁcance.
For the sample size of the animals used in this study, it wasﬁxed
in a prospective manner; no statistical method was used to
predetermine sample size. Mice with the indicated genotypes
were included in the studywithout any randomization.Histologic
analyses were performed in a single-blinded fashion. No blinding
was used for the remaining analyses.
Results
GADD45B expression denotes aggressive malignant disease
across most human cancers
We recently identiﬁed the product of the NF-kB–regulated
gene, GADD45B, as an essential survival factor and novel thera-
peutic target inmultiplemyeloma (24).We therefore investigated
whether GADD45B was involved in any types of malignancy
beyond multiple myeloma. Strikingly, in publicly available
patient datasets, elevated GADD45B expression correlated with
rapid disease progression in 13 of the top 15 solid cancers for
mortality worldwide (36). When patients with prevalent disease
subtypes were stratiﬁed at diagnosis on the basis of GADD45B
expression in the tumor tissues, the patient cohorts expressing
high GADD45B levels exhibited signiﬁcantly shorter RFS and/or
OS than the corresponding cohorts expressing low GADD45B
mRNA levels (Fig. 1A–M). Collectively, these results identify
GADD45b as a hallmark of aggressive pathology across the most
prevalent human cancer types and postulate its general clinical
signiﬁcance in malignant disease.
Gadd45b loss reduces chemically induced hepatocellular
carcinogenesis
The role of IKKb/NF-kB in hepatocellular carcinogenesis
is controversial (16, 17). Indeed, in the widely used DEN
experimental model of HCC, hepatocyte-speciﬁc Ikkb ablation
was previously shown to promote, rather than inhibit, onco-
genesis (33). Therefore, to clarify the basis for the observed
correlation between expression of the IKKb/NF-kB–regulated
effector, GADD45B, and aggressive disease pathology in HCC
datasets (Fig. 1C), we sought to investigate whether GADD45b
was involved in this process. Fifteen-day-old Gadd45b/ and
Gadd45bþ/þ C57BL76J males were treated with a single intra-
peritoneal injection of the carcinogen, DEN, according to an
established protocol for HCC induction (33). As expected, all
Gadd45bþ/þ mice given DEN developed typical HCCs within 9
months (Fig. 2A–E). Interestingly, Gadd45b deletion signiﬁ-
cantly reduced the number of HCCs (Fig. 2A and D). Tumor
surface area and maximum tumor diameter were also markedly
reduced in Gadd45b/mice relative to controls (Fig. 2B and C).
Histologic analysis conﬁrmed the more than 3-fold lower
number of HCCs in Gadd45b/ than Gadd45bþ/þ livers
(Fig. 2F). As typically seen in C57BL76J mice, DEN-induced
tumors predominantly consisted of adenomas, with only few
sporadic carcinomas, hereafter collectively referred to as HCCs.
Similar results were obtained using 129/SvJxC57BL/6Jmice (Sup-
plementary Fig. S1A–S1F). Notably,Gadd45b/ andGadd45bþ/þ
HCCsdisplayed nodifferencewith respect to tumor grade,mitotic
index, or necrosis grade, and similar percentages of proliferating
and apoptotic cells (Supplementary Fig. S1G–S1J). Likewise, the
analysis of cell-cycle regulators and oncogenic factors showed no
difference between Gadd45b/ and Gadd45bþ/þ livers when
comparing corresponding tumor or nontumor tissues (Supple-
mentary Fig. S1K). Hence, opposite to hepatocyte-speciﬁc Ikkb
loss (33),Gadd45b ablation inhibits DEN-induced hepatocellular
carcinogenesis, while having no effect on tumor cell proliferation
or apoptosis.
Gadd45b loss augments tumor-associated macrophage and
T-cell inﬁltration and TLS formation
Despite the otherwise similar histologic and molecular char-
acteristics (Fig. 2E; Supplementary Figs. S1E and S1G–S1K),
Gadd45b/ HCCs contained considerably more and larger
immunoinﬂammatory inﬁltrates than Gadd45bþ/þ tumors
(Fig. 2G; see also Fig. 2E and H; Supplementary Fig. S1E).
Strikingly, in Gadd45b/, but not Gadd45bþ/þ HCCs, intratu-
moral inﬁltrates were also often organized into follicle-like aggre-
gates, reminiscent of tertiary lymphoid structures (TLS; Fig. 2G–J;
see also Fig. 2E; Supplementary Figs. S1E and S2A and S2B),
denoting sites of thriving adaptive immune reactions and favor-
able clinical outcome in multiple human cancers (37). Consis-
tently, whereas only 33% of Gadd45bþ/þ mice contained at least
one HCC featuring TLS-like aggregates (hereafter referred to
Figure 2.
Reduced DEN-induced HCC development with increased intratumoral immunoinﬂammatory inﬁltrates and TLS formation in Gadd45b/ mice. A–C, Number
of tumors (0.5 mm; A), tumor surface area (B), and maximum tumor diameter (C) in livers of Gadd45bþ/þ (n ¼ 9) and Gadd45b/ (n ¼ 12) C57BL/6J males
9 months after DEN injection (20 mg/kg). Values, means  SEM. D, Gross liver morphology in representative mice from A–C. Arrowheads, tumors.
E, Images of hematoxylin and eosin (H&E) staining showing the liver histology in representative mice from A–C. Hatched lines (top), tumor areas. Solid lines (top),
areas magniﬁed in the bottom. Arrowhead (bottom, right), a typical immunoinﬂammatory aggregate. Scales and magniﬁcations are shown. F, Number of
histologically conﬁrmedHCCs per examined liver sections from individualmice inA–C. Each symbol represents an individualmouse. Horizontal lines, means.G andH,
Percentages of HCCs (G) and combinedHCCs and preneoplastic foci (H) containing TLSs inGadd45bþ/þ (n¼ 19) andGadd45b/ (n¼ 26) 129/SvJxC57BL/6Jmales
11months after DEN injection (5mg/kg). Each symbol represents an individualmouse. Horizontal lines, means. I, IHC analysis showing the percentage of positive area
or number of positive cells per ﬁeld at400, as stated, of the indicated immune cell populations in HCCs from G. Values, means SEM (IBA-1: Gadd45bþ/þ, n¼ 47;
Gadd45b/, n ¼ 34. CD8: Gadd45bþ/þ, n ¼ 37; Gadd45b/, n ¼ 33. All other markers: Gadd45bþ/þ, 24  n  26; Gadd45b/, n ¼ 26 or n ¼ 27). J, Images of
hematoxylin and eosin and IHC staining of representative tumor sections from I. Scales and magniﬁcations are shown. A–C and F–I,  , P < 0.05;  , P < 0.01;
 , P < 0.001. See also Supplementary Figs. S1 and S2.
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as TLSs), well-organized TLSs were often found in multiple HCCs
in 80% of Gadd45b/ mice (Supplementary Fig. S2C; see also
Supplementary Fig. S2D).
In both Gadd45b/ and Gadd45bþ/þ HCCs, intratumoral leu-
kocyte inﬁltrates predominantly consisted of lymphocytes and
macrophages, with only few sparse granulocytes (Fig. 2I and J).
However, Gadd45b/ HCCs contained considerably more
F4/80þ and IBA-1þ macrophages and B and T lymphocytes than
Gadd45bþ/þHCCs (Fig. 2I and J; see also Fig. 3A and B). Crucially,
Gadd45b loss also increased the intratumoral inﬁltration byCD8þ
T cells, a hallmark of effective antitumor immune responses
(Fig. 2I and J). Interestingly, whereas the increased numbers of
IBA-1þ macrophages and lymphocytes observed in Gadd45b/
HCCs were mostly due to the greater frequency and larger size of
TLSs, the increased intratumoral F4/80þ macrophage numbers
were mainly attributable to the higher density of these cells
outside TLSs. Plausibly, this distinct effect of Gadd45b loss on
the F4/80þ macrophage distribution within the TME reﬂects the
central role of these cells in sensing "danger" signals and antigens
arising from tumor cells and processing them into cues to elicit
reciprocal adaptive immune reactions (38). Irrespective of the
mechanism(s), our data demonstrate that Gadd45b loss pro-
foundly affects tumor-associated inﬂammation and macrophage
and lymphocyte inﬁltration within DEN-induced HCCs.
Because resident liver macrophages, so-called Kupffer cells,
play a central role in DEN-induced carcinogenesis through a
mechanism that depends on IKK/NF-kB (17, 33), we further
investigated the effect of GADD45b on TAMs. In keeping with
their heightened state of inﬂammation, Gadd45b/ HCCs con-
tained a signiﬁcantly higher number of myeloid-like cells expres-
sing inﬂammatory markers, such as inducible nitric oxide
synthase (iNOS) and cyclo-oxygenase-2 (COX-2), than
Gadd45bþ/þ HCCs (Fig. 3A and B; Supplementary Fig. S2E;
ref. 14). They also containedmarkedlymore IBA-1þmacrophages
within well-organized TLSs expressing MHC-II, a key antigen-
presenting molecule and prototypical proinﬂammatory activa-
tionmarker (Fig. 3C andD; see also Fig. 3A and B; Supplementary
Fig. S2E; ref. 7), thus phenocopying the effects of myeloid-asso-
ciated IKKb/NF-kB inhibition on TAMs (18, 19). Underscoring
the signiﬁcance of these ﬁndings, Gadd45b/HCCs additionally
displayed considerably more TLS-associated cells expressing the
immunoinhibitory enzyme, indoleamine-2,3-dioxygenase
(IDO; Figs. 3E and F), suggesting that the upregulation of immune
checkpoint molecules, such as IDO (3, 4), could conceal the full
immunostimulatory potential of Gadd45b loss. In contrast,
Gadd45b deletion had no effect on alternative TAM activation,
which is more typical of established neoplasias (Figs. 3A and B;
see also Supplementary Fig. S2E; refs. 7, 8). Hence, Gadd45b loss
enhances proinﬂammatory TAM activation within HCCs. Collec-
tively, these ﬁndings indicate that GADD45b plays an essential
role in curbing proinﬂammatory TAM activation, intratumoral
lymphocyte inﬁltration and TLS formation within established
neoplasias.
Gadd45b loss augments DEN-induced hepatocyte toxicity, but
not hepatocyte proliferation
Although in established tumorsmacrophage-driven inﬂamma-
tion has the potential to elicit antitumor immune responses, it
was shown that when it ensues in response to acute DEN-induced
liver damage, this inﬂammation triggers compensatory hepato-
cyte proliferation, thereby facilitating HCC initiation (33). We
therefore examined the effect of Gadd45b loss on the acute liver
response to DEN administration. As expected, in Gadd45bþ/þ
mice, DEN injection induced hepatocyte apoptosis at 48 hours
(Supplementary Fig. S3A and S3B). The number of apoptotic
hepatocytes was modestly increased, in Gadd45b/ mice after
DEN administration, but not at baseline, compared with controls
(Supplementary Fig. S3A and S3B). Circulating liver enzymes,
indicative of hepatocyte damage, were also higher in DEN-treated
Gadd45b/ than Gadd45bþ/þ mice (Supplementary Fig. S3C),
even though the livers of these mice displayed similarly low
numbers of dead cells (Supplementary Fig. S3D and S3E).
Because DEN-induced hepatocyte toxicity involves JNK activa-
tion (33, 39), and GADD45b has the capacity to suppress JNK
signaling in the liver (32), we investigated the effects of Gadd45b
loss onMAPKactivation byDEN.As shown in Supplementary Fig.
S3F, DEN induced strong JNK activation inGadd45bþ/þ livers, but
this activation was unaffected byGadd45b loss. Gadd45b deﬁcien-
cy also had no effect on DEN-induced ERK, p38 or STAT3
signaling, nor did it have any effect on hepatocyte proliferation,
either at baseline or following DEN injection (Supplementary
Fig. S3G and S3H). Hence, Gadd45b loss mildly augments DEN-
induced liver damage, but does not affect hepatocyte proliferation
and is, therefore, unlikely to impact HCC development by affect-
ing the acute liver response to DEN.
Hematopoietic cell–speciﬁc Gadd45b loss reduces DEN-
induced carcinogenesis
Given the association between diminished HCC burden and
increased intratumoral immunoinﬂammatory inﬁltration
observed in Gadd45b/ mice, we hypothesized that GADD45b
promotes hepatocellular carcinogenesis by operating within
immune and inﬂammatory cells. To distinguish between the
oncogenic roles of GADD45b in the TME and the hepatic paren-
chyma, we generated bone marrow chimeras harboring all pos-
sible combinations of tissue-speciﬁc Gadd45b deﬁciency in the
parenchymal tissue and bone marrow–derived cells (Fig. 4A).
Given the importance of Kupffer cells in driving DEN-induced
carcinogenesis (17, 33), chimeric mice were then treated with
clodronate liposomes to deplete endogenous Kupffer cells and
thereby permit liver repopulation with donor-derived Kupffer
cells, following which, mice were administered DEN, along with
the tumor promoter, phenobarbital (Protocol A; Fig. 4A), accord-
ing to an established tumor initiation–promotion protocol (33).
Successful bone marrow–cell reconstitution and host Kupffer
cell liver repopulation with donor-derived Kupffer cells were
conﬁrmed by FACS and immunoﬂuorescence analyses, respec-
tively (Supplementary Fig. S4A-S4B; see also Supplementary
Fig. S4C). As expected, DEN-treated chimeras bearing isogenic
Gadd45bþ/þ or Gadd45b/ tissues (WTBM:WTHost and KOBM:
KOHost, respectively) developed similar numbers of HCCs as their
nontransplanted counterparts (Figs. 4B and C; see also Fig. 2A;
Supplementary Fig. S1A). Notably, however, the ratio between
HCC numbers in these mice was more than 5-folds (Fig. 4B;
compareWTBM:WTHost with KOBM:KOHost) relative to the approx-
imately 2-fold ratio observed in mice treated according to
the tumor initiation–only protocol (Fig. 2A; Supplementary
Fig. S1A), suggesting that Gadd45b loss has a greater impact on
HCC progression than on tumor initiation (discussed below).
Strikingly, selectiveGadd45b ablation in bonemarrow–derived
cells reduced the numbers of HCCs to similar levels as in isogenic
Gadd45b/ mice (Fig. 4B; compare KOBM:WTHost with WTBM:
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Figure 3.
Gadd45b loss increases macrophage inﬁltration and proinﬂammatory TAM activation within HCCs. A, IHC analysis showing the percentage of positive area or
number of positive cells per ﬁeld at 400, as stated, for the indicated macrophage (F4/80, IBA-1) and proinﬂammatory and anti-inﬂammatory activation
markers in HCCs from Fig. 2A–C. B, Images of IHC staining of representative tumor sections from A. Images of Gadd45b/ HCCs are shown for nonorganized
immunoinﬂammatory cell clusters (middle) and well-organized TLSs (right). Insets denote magniﬁed areas at the top right corners. C, Immunoﬂuorescence
analysis showing the percentages of IBA-1þ macrophages expressing MHC-II per ﬁeld at 400 in HCCs from Fig. 2A–C. D, Images of immunoﬂuorescence
staining of representative tumor sections from C. Red, anti–IBA-1; green, anti–MHC-II; blue, DAPI. E, IHC analysis showing the percentage of IDO-positive area
per ﬁeld at 400 in Gadd45bþ/þ and Gadd45b/ HCCs from A. F, Images of IHC staining of representative tumor sections from E. A, C, and E, Values
denote means  SEM (Gadd45bþ/þ, 14  n  30; Gadd45b/, 12  n  15).  , P < 0.05;  , P < 0.01;  , P < 0.001. B, D, and F, Scales and magniﬁcations
are shown. See also Supplementary Figs. S2 and S3.
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WTHost; also compare KOBM:WTHost with KOBM:KOHost). In con-
trast, selective Gadd45b deletion in the hepatic parenchyma did
not signiﬁcantly affect HCC burden (compare WTBM:KOHost with
WTBM:WTHost). In keeping with these ﬁndings, the additional
Gadd45b ablation in bone marrow–derived cells did result in a
signiﬁcant reduction in tumor numbers in Gadd45b/ hosts
(compare WTBM:KOHost with KOBM:KOHost). Hence, selective
Gadd45b loss in hematopoietic-derived cells is sufﬁcient on its
own to fully recapitulate the phenotype of Gadd45b/ mice in
DEN-induced carcinogenesis. We concluded that GADD45b pro-
motes this oncogenic process largely by operatingwithin immune
and inﬂammatory cells.
Gadd45b loss hinders HCC progression
Given that the effect of Gadd45b loss on DEN-induced carci-
nogenesis intensiﬁes in a tumor initiation–promotion model
(Fig. 4B and C), is associated with increased TME-based inﬂam-
mation (Figs. 2G–J and 3A–F; Supplementary Fig. S2A–S2E), and
does not affect the acute hepatocyte proliferative response toDEN
(Supplementary Fig. S3G and S3H), we hypothesized that
GADD45b contributes toHCCprogression, rather than initiation.
As part of so-called "Protocol B" (Fig. 4D),mice of both genotypes
were ﬁrst challenged with DEN and placed on treatment with
phenobarbital, and then adoptively transferred with Gadd45b/
or Gadd45bþ/þ bone marrow, followed by Kupffer cell depletion,
Figure 4.
Reduction of DEN-induced HCC development by Gadd45b deletion in bone marrow–derived cells. A, Summary of the treatment schedule used for Protocol A.
B, Numbers of tumors (0.5 mm) in livers of WTBM:WTHost (n ¼ 40), KOBM:KOHost (n ¼ 25), KOBM:WTHost (n ¼ 36), and WTBM:KOHost (n ¼ 35) bone marrow
chimeras at the time shown in A. C, Gross liver morphology in representative mice from B. D, Summary of the treatment schedule used for Protocol B.
E, Numbers of tumors (0.5 mm) in livers of WTBM:WTHost (n ¼ 24), KOBM:KOHost (n ¼ 23), KOBM:WTHost (n ¼ 24), and WTBM:KOHost (n ¼ 29) bone marrow
chimeras at the time shown in D. F, Gross liver morphology in representative mice from E. A–F, WT, Gadd45bþ/þ; KO, Gadd45b/. Bone marrow chimeras
are identiﬁed as per "bone marrow donor:recipient" genotypes. B and E, Values, means  SEM.  , P < 0.05;  , P < 0.01;  , P < 0.001;  , P < 0.0001.
C and F, Arrowheads, tumors. Also, see Supplementary Fig. S4.
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as for Protocol A. Because, the Gadd45b status of inﬂammatory
cells is modiﬁed 3 months after DEN injection, when
preneoplastic foci have already largely progressed to HCCs
(40), we reasoned that Protocol B would allow to distinguish
between roles of GADD45b in tumor progression versus roles in
tumor initiation.
Successful bonemarrow–cell engraftment andKupffer cell liver
repopulation with donor-derived cells were veriﬁed as for Proto-
col A (Supplementary Fig. S4D and S4E). As expected, 12months
after DEN injection, the ratio between HCC numbers of isogenic
Gadd45bþ/þ and Gadd45b/ mice was similar to that observed
with Protocol A (Fig. 4E and F; compare KOBM:KOHost withWTBM:
WTHost; see also Fig. 4B and C). Strikingly, even when introduced
after tumor initiation had already largely occurred in Gadd45bþ/þ
livers, bone marrow–derived cell-speciﬁc Gadd45b ablation
retained a virtually intact capacity to diminish oncogenesis (Fig.
4E; compare KOBM:WTHost with WTBM:WTHost). Accordingly,
concomitant Gadd45b ablation in the hepatic parenchyma had
no additional effect onHCCburden (compare KOBM:WTHost with
KOBM:KOHost). Reciprocally, the introduction of Gadd45b
þ/þ
bone marrow into Gadd45b/ hosts, 3 months after DEN injec-
tion, was still effective in restoring oncogenesis (compare WTBM:
KOHost with KOBM:KOHost). Notably, these results were broadly
equivalent to those obtained with Protocol A (see Fig. 4B).
Collectively, these ﬁndings reinforce the conclusions that the
GADD45b oncogenic function in DEN-induced tumorigenesis is
largely restricted to the hematopoietic system and impacts
upon tumor progression, while likely having little impact upon
tumor initiation.
TME-associated Gadd45b loss in ﬁbrosarcoma augments TAM
inﬁltration and proinﬂammatory activation, while reducing
tumor growth
To clarify the basis for the tumor-promoting activity of
GADD45b in the TME and its signiﬁcance in the association
between GADD45B expression and aggressive disease pathology
across human cancer types (Figs. 1A–M), we sought to investigate
other model systems of established neoplasia, in which IKK/
NF-kB drives oncogenesis by operating in immunoinﬂammatory
cells. We reasoned that this approach could additionally clarify
the basis for the oncogenic function of IKK/NF-kB itself in these
cells. Indeed, although IKK/NF-kB inhibition in different epithe-
lial cell types was shown to have discordant outcomes on onco-
genesis, this inhibition in inﬂammatory cells, especially those of
the myeloid lineage, has invariably resulted in oncogenesis sup-
pression (16).We chose an initiatedﬁbrosarcomamodel inwhich
hematopoietic cell–speciﬁc NF-kB1/p105 ablation was shown to
augment TME-based inﬂammation and proinﬂammatory TAM
activation, resulting in diminished tumor growth (19). As
expected, subcutaneously implanted MCA-203 ﬁbrosarcomas
grew rapidly in immunocompetent C57BL76J Gadd45bþ/þ mice
(Fig. 5A). Notably, however, tumor growthwasmarkedly reduced
in Gadd45b/ hosts, thereby conﬁrming in a different model
system the essential oncogenic role of GADD45b in the TME.
As seen with HCC (Figs. 2I and J and 3A–D), the Gadd45b/
TME contained a higher number of TAMs than the Gadd45bþ/þ
TME (Fig. 5B; Supplementary Fig. S5A). Fibrosarcomas from
Gadd45b/ mice also contained more T cells than tumors from
Gadd45bþ/þhosts, although at the early time point examined (i.e.,
d19), this T-cell increase had not reached statistical signiﬁcance
(Figs. 5B; Supplementary Fig. S5A). Plausibly, this reﬂected the
rapid evolution of ﬁbrosarcoma allografts relative to endogenous
DEN-induced HCCs and the delayed onset of adaptive relative to
innate immune reactions (see also Figs. 2I and J). Indeed, the
depletion of cytotoxic CD8þ T cells by the use of a CD8-speciﬁc
antibody resulted in a marked increase in ﬁbrosarcoma growth,
completely ablating any inhibitory effect of Gadd45b loss on
oncogenesis (Fig. 5C and D; Supplementary Fig. S5B; compare
tumor growth in Gadd45b/ mice treated with anti-CD8 vs.
control antibody; also note the similar tumor growth in
Gadd45b/ and Gadd45bþ/þ mice treated with the anti-CD8
antibody; see also Supplementary Fig. S5C). These data unequiv-
ocally demonstrate the critical importance of cytotoxic CD8þ
T cells in the antitumor effect of TME-associated Gadd45b loss.
In contrast, TME-inﬁltrating B cells and granulocytes were unaf-
fected by Gadd45b loss.
Underscoring the signiﬁcance of the effects of GADD45b on
TAMs, these cells comprised the major cellular component of the
immunoinﬂammatory inﬁltrate in the Gadd45b/ TME. Strik-
ingly, the Gadd45b/ TME also contained an approximately
4-fold higher number of TAMs expressing the proinﬂammatory
markers, iNOS and COX-2 (14), than the Gadd45bþ/þ TME
(Figs. 5E; Supplementary Fig. S5D). Reciprocally, ﬁbrosarcomas
from Gadd45b/ mice displayed a lower number of Ym-1/
Chi3l3þ TAMs than tumors from Gadd45bþ/þ mice. Other anti-
inﬂammatory activation markers were instead unaffected by
Gadd45b loss (14). Hence, TME-associated Gadd45b ablation
augments TAM inﬁltration, proinﬂammatory TAMactivation, and
CD8þ T-cell–driven antitumor immune responses in ﬁbrosarco-
ma, thus reinforcing our ﬁndings with DEN-induced HCC.
TME-speciﬁc Gadd45b loss augments proinﬂammatory TAM
activation and intratumoral T-cell inﬁltration, while reducing
ovarian oncogenesis
To further understand the general signiﬁcance of GADD45b in
TAM activation and malignant progression, we examined a third
cancer model in which IKK/NF-kB was shown to drive oncogen-
esis by operating in myelomonocytic cells. We used ID8-Luc
ovarian adenocarcinoma allografts because previous studies had
shown that macrophage-speciﬁc IKKb inhibition in this model
reverses the typical anti-inﬂammatory TAM phenotype and
enhances proinﬂammatory TAM activation, thereby causing
tumor regression (18). Consistently, whereas syngeneic ID8-Luc
tumors grew rapidly in the peritoneum of Gadd45bþ/þ mice,
tumor growth was markedly reduced in Gadd45b/ mice (Figs.
5F and G), thus demonstrating that TME-speciﬁc Gadd45b abla-
tion also curbs ovarian oncogenesis.
Notably, intratumoral leukocyte inﬁltrates yielded a higher
number of TAMs, T cells and granulocytes, but not B cells, in
Gadd45b/ compared with Gadd45bþ/þ mice (Fig. 5H). Signif-
icantly, as seen in DEN-induced HCC (Figs. 2I and J), the relative
T-cell abundance in the Gadd45b/ TME was largely due to an
increased inﬂux of CD8þ cytotoxic T cells, which drive effective
antitumor immune reactions (Fig. 5H; refs. 3, 5), rather than
CD4þ T cells. Consistent with the increased immunoreactivity of
the Gadd45b/ TME, a larger proportion of Gadd45b/ than
Gadd45bþ/þ TAMs expressed high surface levels ofMHC-II (Fig. 5I
and J; Supplementary Fig. S5E). Puriﬁed Gadd45b/ TAMs also
expressedhigher levels of other proinﬂammatory genes, including
Nos2, Cxcl9, Cxcl10, Tnfa, and Il6, than Gadd45bþ/þ TAMs,
whereas anti-inﬂammatory activation genes, with the exception
of Ym-1/Chi3l3, were unaffected by Gadd45b loss (Fig. 5K;
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Supplementary Fig. S5F; ref. 14). In keepingwith their heightened
state of immune activation, Gadd45b/ TAMs additionally
expressed higher levels of immune checkpoint molecule-
encoding genes, for example, Ido, Ctla-4, Pd-l1, and B7-h3
(Fig. 5L; refs. 3, 4), thus conﬁrming the observations made with
DEN-induced HCC (Fig. 3E and F). Hence, in three distinct
models of solid cancer, TME-speciﬁc Gadd45b ablation increased
proinﬂammatory TAM activation, and intratumoral macrophage
and CD8þ T-cell inﬁltration (see also Figs. 2G–J, 3A–F, 5B, E, and
H–L; Supplementary Figs. S2E; S5A, S5D, and S5E), resulting in
diminished tumor growth. Interestingly, these effects of Gadd45b
loss on oncogenesis phenocopied the effects of myeloid-speciﬁc
IKKb/NF-kB inhibition (16, 18, 19). Collectively, these ﬁndings
underpin the importance of the TME-speciﬁc role of GADD45b in
curbing tumor-associated inﬂammation and immune inﬁltration
across different cancer types.
Gadd45b loss promotes proinﬂammatory macrophage
activation via a cell-autonomous mechanism
We sought to investigate whether GADD45b mediated its
effects on TAM activation via a cell-autonomous mechanism. We
used an ex vivo coculture model systemmimicking the tumor cell/
macrophage interactions occurring in cancer, in vivo (18). Con-
sistent with our in vivo ﬁndings (Figs. 5E; Supplementary
Fig. S5D), upon coculture with MCA-203 cells, Gadd45b/
BMDMs expressed markedly higher levels of proinﬂammatory
M1-like genes, includingNos2, Tnfa, and Cxcl10, and lower levels
of Arg-1, but not of other anti-inﬂammatory M2-like genes, than
Gadd45bþ/þ BMDMs (Fig. 6A). Similar results were obtained
when Gadd45b/ and Gadd45bþ/þ BMDMs were cocultured
under similar conditions with ID8-Luc carcinoma cells (Supple-
mentary Fig. S6A; see also Figs. 5I–K; Supplementary Fig. S5F).
Hence, GADD45b plays an essential and cell-autonomous role in
restraining proinﬂammatory macrophage activation in response
to cues from tumor cells.
To clarify the mechanisms by which GADD45b governs tumor
cell–induced macrophage activation, we used a tumor cell–free
model system, which employs cytokines and TLR ligands to
polarize macrophages (7, 8). As expected, proinﬂammatory
M1-like genes, as well as known NF-kB target genes, including
Gadd45b, Nfkbia, and Tnfaip3, were strongly upregulated by IFNg
and lipopolysaccharide (LPS) in Gadd45bþ/þ BMDMs (Fig. 6B).
Each of the proinﬂammatory M1-like genes tested, however, was
further signiﬁcantly upregulated in IFNg/LPS-treated Gadd45b/
BMDMs compared with Gadd45bþ/þ BMDMs. Immune check-
point molecule-coding genes, including Ido and Pd-l2, were also
markedly increased in IFNg/LPS-stimulated Gadd45b/ BMDMs
relative to controls (Fig. 6B), in keeping with our in vivo ﬁndings
(Figs. 3E and F and 5L). In contrast, Gadd45b expression was
unaffected by treatment with IL4 and IL13, as was the upregula-
tion of each of the anti-inﬂammatory M2-like genes analyzed
(Fig. 6C). We concluded that GADD45b is required to curb
inﬂammation and M1-like macrophage activation, but is not
directly involved in anti-inﬂammatory M2-like polarization, sug-
gesting that the perturbation of the anti-inﬂammatory activation
proﬁle of Gadd45b/ TAMs, occasionally observed in coculture
systems and in vivo, stemmed from the skewing of these cells
toward a proinﬂammatory activation phenotype. Collectively,
these ﬁndings provide a mechanism for the effect of Gadd45b
loss on tumor-associated inﬂammation and proinﬂammatory
TAM polarization, in vivo.
Gadd45b loss exacerbates proinﬂammatory M1-like
polarization by enhancing p38 signaling
To further the mechanistic understanding of the role of
GADD45b in macrophage polarization, we examined STAT1
and MAPK signaling, which upregulates the M1-like activation
program downstream of IFNg receptor (IFNgR) and TLRs (41).
As shown in Fig. 6D and E, stimulation with IFNg and LPS
activated these pathways, as well as GADD45b expression, in
Gadd45bþ/þ BMDMs. Yet, Gadd45b deletion had no effect on
either STAT1 or ERK phosphorylation, nor did it have any
effect on JNK signaling, nor on NF-kB activation (Fig. 6D and
E). Surprisingly, Gadd45b loss instead markedly augmented
and prolonged IFNg/LPS-induced p38 signaling, at each of
the time points examined (Fig. 6D). We concluded that
GADD45b is required to restrict both the magnitude and
duration of p38 activation during proinﬂammatory macro-
phage polarization.
Because p38 governs inﬂammation and expression of many
of the proinﬂammatory M1-denoting genes deregulated by
Gadd45b loss (42), we hypothesized that GADD45b inhibits
proinﬂammatory macrophage polarization by restraining exac-
erbated p38 signaling. We therefore investigated whether atten-
uating this signaling reversed the effects of Gadd45b loss on
macrophage activation. Notably, treatment with the speciﬁc
Figure 5.
Increased intratumoral immunoinﬂammatory inﬁltration, proinﬂammatory TAM activation, and reduced ﬁbrosarcoma and ovarian carcinoma growth inGadd45b/
mice. A, Volumes of subcutaneous MCA-203 ﬁbrosarcoma allografts in Gadd45bþ/þ (n ¼ 10) and Gadd45b/ (n ¼ 9) mice at the times shown. B, IHC
analysis showing the percentage of positive areas per ﬁeld at 400 of the indicated immune cell populations in MCA-203 tumors from Gadd45bþ/þ (n ¼ 7)
andGadd45b/ (n¼ 8)mice 19 days after tumor cell injection.C,Volumes of subcutaneousMCA-203 ﬁbrosarcoma allografts inGadd45bþ/þ andGadd45b/mice
treated with anti-CD8 or isotype control antibody, as shown, at the times indicated. Gadd45bþ/þ: anti-CD8 (n¼ 9), isotype (n¼ 7); Gadd45b/: anti-CD8 (n¼ 9),
isotype (n ¼ 4). D, Images of representative tumors from C at day 20. E, IHC analysis showing the percentage of positive areas per ﬁeld at 400 of the
indicated proinﬂammatory and anti-inﬂammatory activation markers in the tumors from B. F, Relative luminescence units (RLU) of intraperitoneal ID8-Luc ovarian
tumor allografts in Gadd45bþ/þ (n ¼ 10) and Gadd45b/ (n ¼ 10) mice at the times shown after tumor cell injection. G, Bioluminescence images of
representative mice from F presented as a pseudocolor scale, whereby red and blue denote the highest and lowest photon ﬂux, respectively. H, FACS
analysis showing the percentage of the indicated intratumoral immune cell populations inGadd45bþ/þ (n¼ 12) andGadd45b/ (n¼ 13) mice 60 days after ID8-Luc
tumor cell injection. I, FACS analysis showing the percentage of CD11bþ and F4/80þ double positive TAMs expressing high MHC-II levels (MHC-IIhigh) in ID8-Luc
tumors from H. J, FACS analysis showing the median MHC-II ﬂuorescence intensity of CD11bþ and F4/80þ double positive TAMs in ID8-Luc tumors from H.
H–J, Boxes span between the highest values of the ﬁrst and third quartiles; whiskers extend to the highest and lowest values within 1.5 of the interquartile range.
Lines within boxes, medians. K and L, qRT-PCR showing the relative mRNA levels of the indicated proinﬂammatory activation markers (K) and immune checkpoint
molecules (L) in CD11bþ TAMs from Gadd45bþ/þ (n¼ 22) and Gadd45b/ (n ¼ 10 or n ¼ 12) mice 10 weeks after ID8-Luc cell injection. A–C, E, F, K, and L, Values,
means  SEM. A–C, E, F, and H–L,  , P < 0.05;  , P < 0.01;  , P < 0.001. Also, see Supplementary Fig. S5.
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Figure 6.
Gadd45b loss increases proinﬂammatory macrophage activation by enhancing p38 signaling. A, qRT-PCR showing the relative mRNA levels of the
indicated proinﬂammatory and anti-inﬂammatory genes in BMDMs from Gadd45bþ/þ and Gadd45b/ mice after a 24-hour coculture with MCA-203 cells.
B, qRT-PCR showing the relative mRNA levels of the indicated proinﬂammatory, NF-kB–regulated and immune checkpoint molecule-coding genes in BMDMs
from Gadd45b/ and Gadd45bþ/þ mice after a 4-hour (Nfkbia, Tnfaip3, and Gadd45b) or 12-hour (all other genes) stimulation with LPS and IFNg . C, qRT-PCR
showing the relative mRNA levels of the indicated anti-inﬂammatory genes after a 26-hour stimulation with IL4 and IL13. D and E, Western blots showing
total and phosphorylated (P) proteins in Gadd45bþ/þ and Gadd45b/ BMDMs after stimulation with LPS and IFNg for the times indicated. b-Actin is shown
as loading control. F, qRT-PCR showing the relative mRNA levels of the indicated proinﬂammatory genes in Gadd45b/ BMDMs left untreated () or treated
with LPS and IFNg (þ) for 12 hours in the presence (þ) or absence () of the p38 inhibitor, Vx745 (20mmol/L).A–C and F,Values,means SEM [A,B (top), andF, n¼
4; B (bottom) and C, n ¼ 3].  , P < 0.05; , P < 0.01; , P < 0.001. Also, see Supplementary Fig. S6.
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p38a/b inhibitor, Vx745 (http://www.kinase-screen.mrc.ac.uk/
screening-compounds/348786), downregulated the IFNg/LPS–
dependent induction of each of the proinﬂammatory M1-like
genes that were overactivated by Gadd45b loss to levels similar
to those observed in IFNg/LPS–stimulated Gadd45bþ/þ BMDMs
(Fig. 6F; see also Fig. 6B). Comparable results were obtained
using two additional, structurally unrelated p38 inhibitors, that
is, skepinone-L and SB203580, thus excluding any off-target
effect of Vx745 (Supplementary Fig. S6B and S6C). We con-
cluded that GADD45b suppresses proinﬂammatory macro-
phage activation by selectively downregulating IFNg/LPS–
induced p38 signaling.
Macrophage-speciﬁc Gadd45b loss is sufﬁcient to diminish
oncogenesis
To clarify the cause–effect relationship between macrophage-
speciﬁc Gadd45b deﬁciency and oncogenesis suppression, we
generated mice carrying homozygous loxP-ﬂanked Gadd45b
alleles (Gadd45bF/F mice; Fig. 7A; Supplementary Fig. S7A
and S7B), and crossed them with LysM-cre transgenic mice to
obtainmyeloid-speciﬁcGadd45b-nullmice (Gadd45bDM/DM), after
Cre-mediated recombination (Supplementary Fig. S7C; ref. 33).
PCR analyses conﬁrmed the selective excision of the Gadd45bF
alleles and the resulting ablation of Gadd45b mRNA expression
in Gadd45bDM/DM splenic macrophages, but not splenic B or
T lymphocytes (Fig. 7B and C).
Given that the LysM-cre transgene, which efﬁciently deletes
loxP-targeted alleles in circulating myelomonocytic cells, is not
useful in Kupffer cells (33), Gadd45bDM/DM mice could not be
tested in the DEN HCC model. We therefore used them in the
context of MCA-203 ﬁbrosarcoma allografts. As expected,
MCA-203 tumor growth was unaffected by the presence of
Gadd45bF/F alleles (Fig. 7D and E; see also Fig. 5A). Strikingly,
however, this growth was markedly diminished inGadd45bDM/DM
mice to a similar extent as seen in Gadd45b/ mice (Fig. 7D
and E; see Fig. 5A), indicating that macrophage-speciﬁc Gadd45b
loss is sufﬁcient on its own to fully recapitulate the effect
of complete TME-based Gadd45b deﬁciency on inﬂammation-
driven oncogenesis.
We sought to conﬁrm this macrophage-speciﬁc role of
GADD45b in oncogenesis by using an alternative mouse model.
To this end, ID8-Luc ovarian tumors were allowed to grow in
Gadd45bþ/þmice until they became detectable by bioimaging, at
which point, mice were adoptively transferred with ex vivo cul-
tured Gadd45bþ/þ or Gadd45b/ BMDMs (0 week; Figs. 7F–H).
As expected, following Gadd45bþ/þ BMDM transfer, ovarian
tumors continued to grow rapidly (Figs. 7G and H). In contrast,
the transfer of Gadd45b/ BMDMs resulted in a signiﬁcant
inhibition of tumor growth. As seen with ﬁbrosarcoma (Figs.
7D and E), the effects of macrophage-speciﬁc Gadd45b loss on
ovarian carcinogenesis recapitulated the tumor-suppressive effect
of complete TME-based Gadd45b ablation (Figs. 5F and G).
Together with our ﬁndings withGadd45bDM/DMmice, these results
demonstrate that GADD45b orchestrates the tumor-promoting
activity of the TME across multiple cancer types by operating
in myeloid cells. Collectively, our ﬁndings provide a mechanism
for the immunosuppressive activity of the TME that restricts
tumor-based inﬂammation and CD8þ T-cell trafﬁcking into
tumors and underscore the general signiﬁcance of the NF-kB–
dependent mechanisms mediated by GADD45b in human
malignant disease.
Discussion
We have identiﬁed an essential innate immunity "checkpoint"
governed by the GADD45b-dependent axis of the NF-kB pathway
that counters TME-based inﬂammation and CD8þ T-cell trafﬁck-
ing into tumors, the major barrier to effective anticancer immu-
notherapy (3, 5). In three distinct models of cancers that are
largely refractory to immunotherapies (43–45), myeloid-associ-
ated Gadd45b ablation restored proinﬂammatory TAM activation
and intratumoral CD8þ T-cell inﬁltration, leading to diminished
tumor growth. These ﬁndings uncover a mechanism for the
immunosuppressive activity of the TME that fosters oncogenesis.
They also provide a basis for the anti-inﬂammatory role that IKKb/
NF-kB plays in the myeloid lineage and identify a candidate
therapeutic route in the innate immune system for "reeducating"
TAMs to overcome TME-mediated immunosuppression and,
potentially, resistance to immunotherapies.
The treatment of certain malignancies is being revolutionized
by the development of effective immunotherapies, such as
antagonists of immune checkpoint molecules (4). Yet, the large
majority of patients fail to respond to these treatments, due to the
presence of additional immunoinhibitory mechanisms in the
TME that prevent T-cell access into tumors or cause T-cell exhaus-
tion (3, 5). However, the limited understanding of thesemechan-
isms currently precludes the development of effective treatment
strategies for breaking the TME-mediated resistance to immu-
notherapies. An attractive approach to overcome this resistance
would be to harness the innate immune system to induce tumor-
based inﬂammation and CD8þ T-cell entry and expansion in the
TME. Together, the myeloid-speciﬁc role of IKKb/NF-kB in sup-
pressing proinﬂammatory TAM activation (15) and the central
role of myeloid cells in cancer immune evasion (6, 7) provide a
compelling rationale for therapeutically targeting IKKb/NF-kB
signaling to reprogram TAMs toward a proinﬂammatory activa-
tion phenotype capable of eliciting local antitumor immune
responses (18, 19). Yet, no speciﬁc IKKb/NF-kB inhibitor has so
far been clinically approved.
Our ﬁnding that GADD45b mediates an essential innate
immunoinhibitory mechanism therefore provides an attractive
route downstream in the IKKb/NF-kB pathway to redirect CD8þ
T-cell trafﬁcking into tumors and reactivate silenced CD8þ T-cell–
driven antitumor immune responses. Congruently, in various
cancer types, selective GADD45b ablation in myelomonocytic
cells closely phenocopied the effects of IKKb/NF-kB inactivation
on oncogenesis (15, 16, 18, 19). Importantly, myeloid-speciﬁc
GADD45b deletion appeared to override TME-mediated CD8þ T-
cell exclusion, plausibly through a mechanism involving the
upregulation of CXCR3-binding chemokines, for example,
CXCL9, CXCL10, and CXCL11, which recruit Th-1–type and
CD8þ effector T cells into tumors and extranodal sites of inﬂam-
mation (5, 46). Underscoring the importance of the GADD45b-
mediated function, the depletion of CD8þ T cells completed
abrogated any effect of myeloid-restricted Gadd45b loss on onco-
genesis. Indeed, GADD45b blockade appeared to also enhance
the ability of the TME to support T-cell effector functions by
upregulating multiple inﬂammatory mediators, proinﬂamma-
tory TAM functionalities, and MHC-II molecules. Underscoring
the coordinated nature of its multiple effects on the immune
system, GADD45b ablation further imparted anatomic organiza-
tion to adaptive immune reactions, enabling them to assemble
into well-conﬁgured TLSs within endogenously arisen tumors.
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Figure 7.
Suppression of oncogenesis by macrophage-speciﬁc Gadd45b deletion. A, The targeting strategy for generating the loxP-ﬂanked Gadd45b allele (Gadd45bF).
B, PCR detecting the wild-type (Gadd45bþ), Gadd45bF, or excised (Gadd45bD) Gadd45b alleles in the indicated tissues from Gadd45bþ/þ (þ/þ), Gadd45bþ/F (þ/F),
Gadd45bF/F (F/F), or Gadd45bF/F;LysM-cre (DM/DM) mice. C, qRT-PCR showing the relative Gadd45b mRNA levels in the indicated tissues isolated from
Gadd45bF/F (F/F) or Gadd45bF/F;LysM-cre (DM/DM) mice. D, Volumes of subcutaneous MCA-203 ﬁbrosarcoma allografts in Gadd45bDM/DM (n ¼ 9) and Gadd45bF/F
(n ¼ 8) mice at the times shown. E, Images of representative tumors from D at day 21. F, Summary of the cell injection schedule used in G and H. G, Relative
luminescence units (RLU) of intraperitoneal ID8-Luc ovarian tumor allografts inGadd45bþ/þmice at the times indicated after intraperitoneal injection ofGadd45bþ/þ
(n¼ 9) or Gadd45b/ (n¼ 12) BMDM pools. H, Bioluminescence images of representative mice from G presented as a pseudocolor scale as in Fig. 5G. I, Schematic
representation of the oncogenic function of GADD45b in macrophages. C, D, and G, Values, means SEM.  , P < 0.05;  , P < 0.01. Also, see Supplementary Fig. S7.
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Although Pikarsky and colleagues recently suggested that TLSs
facilitate HCC initiation and early promotion, their study inves-
tigated TLS formation in the context of the preneoplastic hepatic
parenchyma and inﬂamed neoplastic liver outside HCCs (47).
Indeed, T- and B-cell immunity has been previously shown to
counter DEN-induced HCC development in mouse models (47,
48), and intratumoral TLSs have been shown to portend a
favorable clinical outcome in the majority of human cancers,
including HCC (37, 49). Future studies will determine the precise
mechanisms by which GADD45b curbs TME-based TLS forma-
tion and cytotoxic CD8þ T-cell trafﬁcking and activation, as well
as how these mechanisms relate to the GADD45b-mediated anti-
inﬂammatory function in myeloid cells. Irrespective of the
mechanisms, the profound effects of Gadd45b loss on macro-
phage and T-cell accumulation in the TME and intratumoral TLS
formation underscore the broad clinical potential of the
GADD45b-dependent anti-inﬂammatory axis of the IKK/NF-kB
pathway in anticancer immunotherapy.
Because GADD45b also serves as an essential NF-kB–
regulated inhibitor of cancer cell apoptosis (24), our ﬁnding
of its unexpected function in the innate immune system
demonstrates that a single pivotal axis of the IKK/NF-kB path-
way, that is, the GADD45b-dependent axis, integrates the
oncogenic mechanism suppressing tumor cell apoptosis with
the mechanism restraining TME-based inﬂammation and T-cell
inﬁltration. Hence, GADD45b serves as a central downstream
hub in the IKK/NF-kB pathway linking cancer and inﬂamma-
tion. Surprisingly, GADD45b appears to perform these onco-
genic functions via separable, tissue-speciﬁc mechanisms,
attenuating proinﬂammatory p38 signaling within TAMs to
restrain proinﬂammatory activation, while inhibiting apoptosis
of cancer cells by suppressing JNK/MKK7 signaling (Fig. 7I;
ref. 24). Future studies will clarify the precise mechanism(s) by
which GADD45b curbs p38 activation in myeloid cells and
conﬁrm the role of this mechanism in oncogenesis. Irrespective
of these mechanism(s), our results postulate that targeting the
IKKb/NF-kB pathway through GADD45b inhibition provides a
candidate therapeutic route to counter oncogenesis by reversing
TME-mediated immunosuppression and, at the same time,
inducing apoptosis of cancer cells, thereby affording dual
clinical beneﬁt. Indeed, a combination of oncogenic mechan-
isms mediated by GADD45b in malignant and TME-based
myeloid cells likely underpins the correlations between elevat-
ed GADD45B expression and poor clinical outcome observed in
the large majority of human cancers.
To circumvent the limitations of IKK/NF-kB–targeting agents,
we recently adopted the strategy of therapeutically targeting a
nonredundant, pathogenically critical axis of the NF-kB path-
way, similarly mediated by GADD45b, in multiple myeloma,
rather than NF-kB globally (24, 50). Initial results from the ﬁrst-
in-human clinical study of GADD45b/MKK7–targeting thera-
peutics in patients with multiple myeloma preliminarily indi-
cate the clinical safety of these agents, alongside cancer-selective
pharmacodynamic response (L. Tornatore and G. Franzoso,
unpublished observations). These encouraging early clinical
results suggest that it may be possible to similarly target the
GADD45b-binding factor regulating p38 signaling in myeloid
cells, to elicit antitumor inﬂammation. Notably, by converting
tumors lacking a spontaneous CD8þ T-cell inﬁltrate into CD8þ
T-cell–inﬁltrated tumors and, concurrently, upregulating
immune checkpoint molecules, for example, IDO and PD-1
ligands, innate immunotherapies targeting GADD45b could
conceivably overcome primary resistance to adaptive immu-
notherapies, and thereby increase response rates in currently
recalcitrant cancer patient subsets (3, 5).
Further studies will clarify the clinical beneﬁt of combining
GADD45b inhibitors with conventional immunotherapies.
Notwithstanding, the remarkable consistency of the effects of
myeloid-speciﬁc Gadd45b deletion on oncogenesis and the
widespread correlation of GADD45B expression with aggressive
disease pathology across most human cancer types underscore
the general clinical signiﬁcance of the GADD45b-mediated
mechanism and, consequently, the potential of GADD45b-
targeting therapeutics in human malignant disease. The new
added focus provided by our current ﬁndings of a role of
GADD45b in innate immune regulation will also invigorate
the drug discovery effort to develop novel GADD45b-targeting
immunotherapeutics for safely and effectively treating onco-
logical diseases.
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